File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: In silico structure-based discovery of a SARS-CoV-2 main protease inhibitor

TitleIn silico structure-based discovery of a SARS-CoV-2 main protease inhibitor
Authors
Issue Date2021
PublisherIvyspring International Publisher. The Journal's web site is located at http://www.biolsci.org/index.htm
Citation
International Journal of Biological Sciences, 2021, v. 17 n. 6, p. 1555-1564 How to Cite?
AbstractThe Coronavirus Disease 2019 (COVID-19) pandemic caused by the novel lineage B betacoroanvirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant mortality, morbidity, and socioeconomic disruptions worldwide. Effective antivirals are urgently needed for COVID-19. The main protease (Mpro) of SARS-CoV-2 is an attractive antiviral target because of its essential role in the cleavage of the viral polypeptide. In this study, we performed an in silico structure-based screening of a large chemical library to identify potential SARS-CoV-2 Mpro inhibitors. Among 8,820 compounds in the library, our screening identified trichostatin A, a histone deacetylase inhibitor and an antifungal compound, as an inhibitor of SARS-CoV-2 Mpro activity and replication. The half maximal effective concentration of trichostatin A against SARS-CoV-2 replication was 1.5 to 2.7µM, which was markedly below its 50% effective cytotoxic concentration (75.7µM) and peak serum concentration (132µM). Further drug compound optimization to develop more stable analogues with longer half-lives should be performed. This structure-based drug discovery platform should facilitate the identification of additional enzyme inhibitors of SARS-CoV-2.
Persistent Identifierhttp://hdl.handle.net/10722/304900
ISSN
2023 Impact Factor: 8.2
2023 SCImago Journal Rankings: 2.114
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorWen, L-
dc.contributor.authorTang, K-
dc.contributor.authorChik, KKH-
dc.contributor.authorChan, CCY-
dc.contributor.authorTsang, OL-
dc.contributor.authorLiang, R-
dc.contributor.authorCao, J-
dc.contributor.authorHuang, Y-
dc.contributor.authorLuo, C-
dc.contributor.authorCai, JP-
dc.contributor.authorYe, ZW-
dc.contributor.authorYin, F-
dc.contributor.authorChu, H-
dc.contributor.authorJin, DY-
dc.contributor.authorYuen, KY-
dc.contributor.authorYuan, S-
dc.contributor.authorChan, JFW-
dc.date.accessioned2021-10-05T02:36:49Z-
dc.date.available2021-10-05T02:36:49Z-
dc.date.issued2021-
dc.identifier.citationInternational Journal of Biological Sciences, 2021, v. 17 n. 6, p. 1555-1564-
dc.identifier.issn1449-2288-
dc.identifier.urihttp://hdl.handle.net/10722/304900-
dc.description.abstractThe Coronavirus Disease 2019 (COVID-19) pandemic caused by the novel lineage B betacoroanvirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant mortality, morbidity, and socioeconomic disruptions worldwide. Effective antivirals are urgently needed for COVID-19. The main protease (Mpro) of SARS-CoV-2 is an attractive antiviral target because of its essential role in the cleavage of the viral polypeptide. In this study, we performed an in silico structure-based screening of a large chemical library to identify potential SARS-CoV-2 Mpro inhibitors. Among 8,820 compounds in the library, our screening identified trichostatin A, a histone deacetylase inhibitor and an antifungal compound, as an inhibitor of SARS-CoV-2 Mpro activity and replication. The half maximal effective concentration of trichostatin A against SARS-CoV-2 replication was 1.5 to 2.7µM, which was markedly below its 50% effective cytotoxic concentration (75.7µM) and peak serum concentration (132µM). Further drug compound optimization to develop more stable analogues with longer half-lives should be performed. This structure-based drug discovery platform should facilitate the identification of additional enzyme inhibitors of SARS-CoV-2.-
dc.languageeng-
dc.publisherIvyspring International Publisher. The Journal's web site is located at http://www.biolsci.org/index.htm-
dc.relation.ispartofInternational Journal of Biological Sciences-
dc.rightsInternational Journal of Biological Sciences. Copyright © Ivyspring International Publisher.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleIn silico structure-based discovery of a SARS-CoV-2 main protease inhibitor-
dc.typeArticle-
dc.identifier.emailChik, KKH: kennchik@hku.hk-
dc.identifier.emailTsang, OL: oltsang@hku.hk-
dc.identifier.emailHuang, Y: lyqhuang@hku.hk-
dc.identifier.emailLuo, C: cuiting@hku.hk-
dc.identifier.emailCai, JP: caijuice@hku.hk-
dc.identifier.emailYe, ZW: zwye@hku.hk-
dc.identifier.emailChu, H: hinchu@hku.hk-
dc.identifier.emailJin, DY: dyjin@hku.hk-
dc.identifier.emailYuen, KY: kyyuen@hkucc.hku.hk-
dc.identifier.emailYuan, S: yuansf@hku.hk-
dc.identifier.emailChan, JFW: jfwchan@hku.hk-
dc.identifier.authorityChu, H=rp02125-
dc.identifier.authorityJin, DY=rp00452-
dc.identifier.authorityYuen, KY=rp00366-
dc.identifier.authorityYuan, S=rp02640-
dc.identifier.authorityChan, JFW=rp01736-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.7150/ijbs.59191-
dc.identifier.pmid33907519-
dc.identifier.pmcidPMC8071767-
dc.identifier.scopuseid_2-s2.0-85105107681-
dc.identifier.hkuros326085-
dc.identifier.volume17-
dc.identifier.issue6-
dc.identifier.spage1555-
dc.identifier.epage1564-
dc.identifier.isiWOS:000697605800014-
dc.publisher.placeAustralia-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats